Harrow, Inc. (HROW)
(Delayed Data from NSDQ)
$10.85 USD
-0.97 (-8.21%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $10.84 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HROW 10.85 -0.97(-8.21%)
Will HROW be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HROW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HROW
New Strong Sell Stocks for November 14th
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
HROW: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
Harrow Health (HROW) Gains As Market Dips: What You Should Know
Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know
Other News for HROW
HROW, HCAT and EGRX are among after hour movers
Craig-Hallum bullish on Harrow, initiates with a Buy
Harrow initiated with bullish view at Craig-Hallum
Analysts Offer Insights on Healthcare Companies: Lonza Group Ltd (Six Swiss: CH:LONN), Harrow Health (HROW) and Innoviva (INVA)
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing